1292836-05-5

Basic information

• Product Name: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate
• Synonyms: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate;N-[(1S)-1-[[(2S)-2-(5-Bromo-1H-imidazol-2-yl)-1-pyrrolidinyl]carbonyl]-2-methylpropyl]carbamic acid methyl ester;EOS-61044;methyl ((S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate(WXG03511)
• CAS NO: 1292836-05-5
• Molecular Formula: C₁₄H₂₁BrN₄O₃
• Molecular Weight: 373.24554
• Mol File: 1292836-05-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 609.8±55.0 °C(Predicted)
• Appearance: /
• Density: 1.443±0.06 g/cm3(Predicted)
• PKA: 11.13±0.10(Predicted)
• CAS DataBase Reference: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate(1292836-05-5)
• EPA Substance Registry System: methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate(1292836-05-5)

Safety Data

• Hazardous Substances Data: 1292836-05-5(Hazardous Substances Data)

Usage

General Description

Methyl(S)-1-((S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-ylcarbamate is a complex organic compound that is commonly used in the field of medicinal chemistry. It is a carbamate derivative with a methyl group attached to the carbonyl carbon, as well as a pyrrolidin-1-yl group linked to the carbamate nitrogen. The compound also contains a bromine-substituted imidazole ring and a branched alkyl chain. The unique structure of this chemical makes it a potentially valuable building block for the synthesis of various pharmaceuticals and biologically active compounds. Further research and development of this compound could lead to the discovery of new drugs with therapeutic applications.

Upstream product

• 1240893-76-8 (S)-2-(4,5-dibromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1007882-59-8 (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1007882-58-7 (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 72-18-4 L-valine 
• 1258253-82-5 (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 69610-41-9 Boc-L-Pro-H 
• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 1007882-59-8 (S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1258234-18-2 (S)-5-bromo-2-(pyrrolidin-2-yl)-1H-imidazole hydrochloride 

Downstream Products

• 1613081-64-3 dimethyl((2S,2’S)-((2S,2’S)-2,2’-(5,5’-((S)-6-(2-cyclopropylthiazol-5-yl)-1-fluoro-6H-benzo[5,6][1,3]oxazino[3,4-a]indole-3,10-diyl)bis(1H-imidazole-5,2-diyl))bis(pyrrolidine-2,1-diyl))bis(3methyl-1oxobutane-2,1-diyl))dicarbamate 
• 1370468-36-2 N,N'-[[(6S)-6-phenyl-6H-indolo[1,2-c][1,3]benzoxazine-3,10-diyl]bis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl-[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]bis[carbamic acid] C,C'-dimethyl ester 
• 1620546-33-9 C₄₂H₅₂FN₉O₇ 
• 1613081-63-2 C₅₂H₅₄F₂N₁₀O₇S 
• 1620546-02-2 C₃₈H₃₃ClF₂N₆O₄S 
• 1620545-45-0 C₅₂H₆₁FN₁₀O₇S 
• 1620546-33-9 C₄₂H₅₂FN₉O₇ 
• 1620544-87-7 C₅₂H₅₄F₂N₁₀O₇S 
• 1620546-02-2 C₃₈H₃₃ClF₂N₆O₄S 
• 1370647-84-9 C₅₂H₆₁N₉O₈ 
• 1370647-67-8 C₅₂H₅₇N₉O₈ 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS

A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES

The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.